Xebra to Receive Cannabis Authorizations from Mexican FDA Imminently

Rhea-AI Summary

Xebra Brands Ltd. (CSE: XBRA) (OTCQB: XBRAF) has received direction from the court for the Mexican Health Regulatory Agency (COFEPRIS) to grant all necessary cannabis authorizations to its subsidiary, Xebra Mexico. This follows an irrevocable injunction issued by the Supreme Court in December 2021. Although the authorizations are expected shortly, Xebra may take slightly longer to ensure conditions are satisfactory. CEO Jay Garnett highlighted that this positions Xebra as a first mover in Mexico's CBD market, which has significant potential.

Positive

• Court ruling favors Xebra, directing COFEPRIS to issue cannabis authorizations.
• Xebra poised to be first mover in Mexico's CBD market, expected to capitalize on significant market potential.
• Authorization will allow Xebra to commercialize a wide range of CBD products.

Negative

• Delay in authorization issuance may impact immediate operations.
• COFEPRIS officials face criminal prosecution if they do not comply, indicating potential bureaucratic hurdles.

VANCOUVER, BC, Sept. 29, 2022 /PRNewswire/ - Xebra Brands Ltd. ("Xebra") (CSE: XBRA) (OTCQB: XBRAF) (FSE: 9YC), a cannabis company, is pleased to announce that the Mexican Health Regulatory Agency (the Mexican FDA) (the "COFEPRIS"), has been directed by the court authorities to grant Xebra's wholly owned Mexican subsidiary, Desart MX, SA de CV ("Xebra Mexico"), all applicable cannabis authorizations, pursuant to the irrevocable injunction granted by the Supreme Court in December 2021.  Under pertinent laws, COFEPRIS officials face criminal prosecution if they do not issue the authorizations within three (3) business days, however Xebra expects the process to take marginally longer, as it coordinates with the COFEPRIS to ensure that the terms and conditions of the authorizations are to Xebra's satisfaction.  Notwithstanding the extra time to engage with the COFEPRIS, Xebra fully expects the authorizations to be granted no later than October.

"Xebra is only days away to being the outright first mover in the Mexican CBD market, said Jay Garnett, CEO of Xebra. "Mexico has the potential to be one of the largest CBD consumer markets in the world, and for the foreseeable future, only Xebra will have the legal authorizations to fully commercialize that demand vertically from field to manufacturing and sales."

Xebra Mexico's injunction applies specifically to cannabis with low-levels of THC (under 1%), therefore, in practical terms, to hemp cultivation and processing, and to the manufacture and sale of mainly CBD products, such as tinctures, oils, topicals, edibles, beverages, concentrates, distillates, emulsions, and biomass etc., and certain uses of the cannabis flower. Opportunities in the hemp plastics industries have also been identified.

More information will be provided on Xebra's Mexican plans in due course.

Jay Garnett
CEO

Certain information contained in this press release constitutes forward-looking statements under applicable securities laws. Any statements that are not statements of historical fact may be deemed to be forward-looking statements, these include, without limitation, statements regarding Xebra Brands Ltd.'s expectations in respect of its ability to successfully execute its business plan or business model; its ability to provide economic, environmental, social, or any benefits of any type, in the communities it operates in or may operate it in the future; its ability to be a first mover in a country, or to obtain or retain government licenses, permits or authorizations in general, or specifically in Mexico, Canada, or elsewhere, including cannabis authorizations from the Mexican Health Regulatory Agency (COFEPRIS) and the timing of such permits or authorizations; its ability to successfully apply for and obtain trademarks and other intellectual property in any jurisdiction; its ability to be cost competitive; its ability to commercialize, cultivate, grow, or process hemp or cannabis in Mexico, Canada, or elsewhere and related plans and timing; its ability to manufacture, commercialize or sell cannabis-infused beverages, wellness products, or other products in Mexico, Canada, or elsewhere; its ability to launch, commercialize or to sell Vicious Citrus Lemonade or any additional cannabis infused beverage brands or products, at any time, in any jurisdiction, and its related plans and claims, including market interest and availability; its ability to commercialize or to sell Elements wellness products in any jurisdiction at any time; its ability to create wellness products that have a therapeutic effect or benefit; plans for future growth and the direction of the business; financial projections including expected revenues, gross profits, and EBITDA (which is a non-GAAP financial measure); plans to increase product volumes, the capacity of existing facilities, supplies from third party growers and contractors; expected growth of the cannabis industry generally; management's expectations, beliefs and assumptions in general, including manufacturing costs, production activity and market potential in Mexico or any jurisdiction; events or developments that XEBRA expects to take place in the future; general economic conditions; and other risk factors described in the prospectus of the Company dated September 30, 2021. All statements, other than statements of historical facts, are forward-looking information and statements. The words "aim", "believe", "expect", "anticipate", "contemplate", "target", "intends", "continue", "plans", "budget", "estimate", "may", "will", and similar expressions identify forward-looking information and statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by XEBRA as of the dates of such statements, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Known and unknown factors could cause actual results to differ materially from those projected in the forward-looking statements. Such factors include, but are not limited to, the inability of XEBRA to generate sufficient revenues or to raise sufficient funds to carry out its business plan; changes in government legislation, taxation, controls, regulations and political or economic developments in various countries; risks associated with agriculture and cultivation activities generally, including inclement weather, access to supply of seeds, poor crop yields, and spoilage; compliance with import and export laws of various countries; significant fluctuations in cannabis prices and transportation costs; the risk of obtaining necessary licenses and permits; inability to identify, negotiate and complete a potential acquisition for any reason; the ability to retain key employees; dependence on third parties for services and supplies; non-performance by contractual counter-parties; general economic conditions; and the continued growth in global demand for cannabis products and the continued increase in jurisdictions legalizing cannabis; and the timely receipt of regulatory approval for license applications. In addition, there is no assurance Xebra will: be a low-cost producer or exporter; obtain a dominant market position in any jurisdiction; have products that will be unique; launch other Vicious Citrus SKUs; or monetize any asset sales from its Colombian and Dutch subsidiaries. The foregoing list is not exhaustive and XEBRA undertakes no obligation to update or revise any of the foregoing except as required by law. Many of these uncertainties and contingencies could affect XEBRA's actual performance and cause its actual performance to differ materially from what has been expressed or implied in any forward-looking statements made by, or on behalf of, XEBRA. Readers are cautioned that forward-looking statements are not guarantees of future performance and readers should not place undue reliance on such forward-looking statements. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those set out in such statements.

View original content to download multimedia:https://www.prnewswire.com/news-releases/xebra-to-receive-cannabis-authorizations-from-mexican-fda-imminently-301636432.html

SOURCE Xebra Brands Ltd.

FAQ

What cannabis authorizations is Xebra Brands Ltd. expecting from COFEPRIS?

Xebra is expecting all applicable cannabis authorizations for its subsidiary, Xebra Mexico, to be granted soon.

When will Xebra Brands Ltd. receive cannabis authorizations from COFEPRIS?

Xebra expects to receive the authorizations no later than October 2022.

How does the court ruling affect Xebra's stock (XBRAF)?

The court ruling positions Xebra as a first mover in the Mexican CBD market, potentially driving future stock performance.

What products will Xebra Mexico be able to commercialize under the new authorizations?

Xebra Mexico will focus on low-THC products, including tinctures, oils, topicals, edibles, and beverages.

What market potential does CEO Jay Garnett see for Xebra in Mexico?

CEO Jay Garnett believes Mexico has the potential to become one of the largest CBD consumer markets in the world.